ORIC: Advancing late-stage cancer therapies with strong efficacy, safety, and major market potential
Two late-stage oncology programs, rinzimetostat and enozertinib, are advancing through pivotal trials targeting high unmet needs in prostate cancer and NSCLC, respectively. Both show strong efficacy, safety, and blockbuster commercial potential, with a robust cash position supporting development th…